| European Case Law Identifier: | ECLI:EP:BA:2024:T164823.20240522 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 22 May 2024 | ||||||||
| Case number: | T 1648/23 | ||||||||
| Application number: | 12805432.7 | ||||||||
| IPC class: | C07K 16/28 A61K 39/395 A61P 35/02 A61P 37/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Binding molecules for BCMA and CD3 | ||||||||
| Applicant name: | Amgen Research (Munich) GmbH Amgen Inc. |
||||||||
| Opponent name: | AbbVie Inc. Janssen Biotech, Inc. Regeneron Pharmaceuticals, Inc. James Poole Limited Mathys & Squire LLP Sanofi |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Termination of the appeal proceedings - text or agreement to text withdrawn by patent proprietor | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Summary of Facts and Submissions
I. The patent proprietors (appellants) filed an appeal against the decision by the opposition division to revoke European patent No 2 780 375.
II. The board appointed oral proceedings, and in a subsequent communication pursuant to Article 15(1) RPBA, provided its preliminary appreciation of some matters concerning the appeal.
III. During the oral proceedings before the board, which took place on 22 May 2024, the appellants withdrew all requests on file, withdrew their consent and agreement under Article 113(2) EPC to the text of the patent as granted, and indicated that they would not be filing a replacement text.
Reasons for the Decision
1. According to the principle of party disposition established by Article 113(2) EPC, the EPO shall examine and decide on the European patent only in the text submitted to it or agreed upon by the proprietor of the patent.
2. In view of the patent proprietors' statement during the oral proceedings (point III. above), there is no approved text on the basis of which the board could consider the appeal and examine whether a ground for opposition prejudices the maintenance of the patent. It is also no longer possible to take a decision as to substance because the absence of an approved text precludes any substantive examination of the alleged impediments to patentability (T 186/84, OJ 1986, 79, point 5 of the Reasons; T 646/08, point 4 of the Reasons and T 2434/18, point 4 of the Reasons).
3. In a situation such as the present one, where the patent proprietors have appealed a decision of the opposition division revoking their patent and where the appeal becomes devoid of subject-matter for substantive examination following the withdrawal of the patent proprietors' agreement to any text for the maintenance of the patent, the appeal proceedings are to be terminated, and the decision under appeal becomes final (see T 728/11, point 3; T 477/22, point 3).
Order
For these reasons it is decided that:
The appeal proceedings are terminated.
